

US approves radiation-based prostate cancer drug

15 May 2013

(AP)—The U.S. Food and Drug Administration has approved a new injectable drug that uses radiation to treat advanced prostate cancer that has spread to the bones.

The FDA said Wednesday it approved the drug, Xofigo from Bayer Pharmaceuticals, for men whose cancer has grown into bone tumors even after receiving medication or surgery to lower testosterone. The hormone spurs growth of [prostate tumors](#).

Regulators approved Xofigo based on a study of 809 men with advanced prostate cancer who received the drug or placebo. Patients taking Xofigo typically lived 14 months compared to 11.2 months for those taking placebo.

Xofigo's side effects include nausea and diarrhea.

© 2013 The Associated Press. All rights reserved.

APA citation: US approves radiation-based prostate cancer drug (2013, May 15) retrieved 16 September 2021 from <https://medicalxpress.com/news/2013-05-radiation-based-prostate-cancer-drug.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.